660862-82-8

Basic information

• Product Name: Piperazine, 2-(phenoxymethyl)-, (2R)-
• CAS NO: 660862-82-8
• Molecular Formula: C11H16N2O
• Molecular Weight: 192.261
• Mol File: 660862-82-8.mol

Chemical Properties

• CAS DataBase Reference: Piperazine, 2-(phenoxymethyl)-, (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 2-(phenoxymethyl)-, (2R)-(660862-82-8)
• EPA Substance Registry System: Piperazine, 2-(phenoxymethyl)-, (2R)-(660862-82-8)

Safety Data

• Hazardous Substances Data: 660862-82-8(Hazardous Substances Data)

Upstream product

• 1450620-52-6 tert-butyl (3aR)-1,1-dioxotetrahydro-1H-1λ⁶-[1,2,3]oxathiazolo[3,4-a]pyrazine-5(3H)-carboxylate 
• 1450620-51-5 tert-butyl (3aR)-1-oxotetrahydro-1H-1λ⁴-[1,2,3]oxathiazolo[3,4-a]pyrazine-5(3H)-carboxylate 
• 278788-66-2 (R)-tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate 
• 1589081-70-8 (R)-3-phenoxymethylpiperazine-1-carboxylic acid tert-butyl ester 
• 1383941-48-7 C₂₅H₂₈N₂O 

Relevant articles and documents

AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C

The present invention provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.

PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES

Described herein are compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, S, and O; Alk is (C1-4) alkylene or hydroxy substituted (C1-4) alkylene; X is oxygen or sulfur; R1 is hydrogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, or (C1-4) alkyl, wherein the (C1-4) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH2CH2OH, or -CN; R2 is H, halogen, (C1-6) fluoroalkyl, (C1-6) cycloalkyl, OR4, SR4, N02, CN, COR4, C(O)OR4, CONR5R6 , NR5R6, S02NR5R6, NR5COR4, NR5SO2R4, optionally substituted aromatic, or (C1-6) alkyl, wherein (C1-6) alkyl is unsubstituted or substituted with a hydroxy group; R3 is hydrogen, (C1-6) fluoroalkyl, (C2-6) alkenyl, Ar, (C1-4)alkyl-Ar, or (C1-4) alkyl wherein (C1-4) alkyl is unsubsituted or substituted with a phenyl; R4 is hydrogen, (C1-6 alkyl, (C1-6) fluoroalkyl, or optionally substituted aromatic; R5 and R6 are independently hydrogen, (C1-6) alkyl, or optionally substituted aromatic, R7 is hydrogen, (C1-6) alkyl, (C1-6) fluoroalkyl, or optionally substituted aromatic; R8 and R9 are independently hydrogen, (C1-6) alkyl, or optionally substituted aromatic; Ar is optionally substituted phenyl, napthyl, monocyclic heteroaromatic or bicyclic heteroaromatic; Z1 and Z2 are independently selected from hydrogen, halogen, (C1-6) alkyl, (C1-6) fluoroalkyl, OR7, SR7, NO2, CN, COR7, CONR8R9, NR8R9, and optionally substituted aromatic; and all salts, solvates, optical and geometric isomers, and crystalline forms thereof. Also, described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treament of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I).